Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Epstein-Peterson ZD, et al.
Haematologica
August 2023
Authors and Affiliates
Zachary D. Epstein-Peterson1 , Esther Drill2 , Umut Aypar3 , Connie Lee Batlevi1 , Philip Caron1 , Ahmet Dogan3 , Pamela Drullinsky1 , John Gerecitano1 , Paul A. Hamlin1 , Caleb Ho3 , Allison Jacob4 , Ashlee Joseph1 , Leana Laraque1 , Matthew J. Matasar1 , Alison J. Moskowitz1 , Craig H. Moskowitz1 , Chelsea Mullins4 , Colette Owens1 , Gilles Salles1 , Heiko Schöder5 , David J. Straus1 , Anas Younes1 , Andrew D. Zelenetz1 , and Anita Kumar1 1 Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center 2Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center 3Department of Pathology, Memorial Sloan Kettering Cancer Center 4Adaptive Biotechnologies, Seattle, WA, USA 5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA